What is the role of intermittent androgen therapy in the treatment of metastatic and advanced prostate cancer?

Updated: Dec 29, 2020
  • Author: Martha K Terris, MD, FACS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print


Intermittent androgen suppression is a well-established treatment offered to patients with advanced prostate cancer; however, it is not considered the standard of care. [26, 27] Some indications for androgen-withdrawal therapy include newly diagnosed metastatic disease, localized disease with high risk of systemic relapse, prostate-specific antigen (PSA) level rise during treatment, lack of tolerance for side effects, and biochemical failure after local therapy.

Intermittent androgen suppression may delay androgen-independent cancer and increase quality of life (ie, fewer issues regarding potency and libido). Ongoing research is investigating the utility of intermittent treatment.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!